Document is current
Any future updates will be listed below
-
Authors
van der Pol, Simon https://orcid.org/0000-0003-1784-1001
Jansen, Danielle E. M. C.
van der Velden, Alike W. https://orcid.org/0000-0003-4881-038X
Butler, Christopher C.
Verheij, Theo J. M.
Friedrich, Alex W.
Postma, Maarten J.
van Asselt, Antoinette D. I. https://orcid.org/0000-0001-7705-9906
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (820755)
- License Information
-
More Information
Article History
Accepted: 29 May 2022
First Online: 29 June 2022
Declarations
:
: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.
: Maarten J. Postma reports grants and personal fees from various pharmaceutical industries, all outside the submitted work. He holds stocks in Pharmacoeconomics Advice Groningen (PAG Ltd) and is advisor to Asc Academics, all pharmacoeconomic consultancy companies. AvdV reports educational fees from Reckitt Benckiser. The other authors have nothing to disclose.
: The R code of the model is available from: (version 1.1.0).
: Concept and design: SvdP, CB, AWF, MJP, ADIvA. Acquisition of data: SvdP, AvdV, CCB, TJMV. Analysis and interpretation of data: SvdP, DEMCJ, CCB, TJMV, AWF, MJP, ADIvA. Drafting of the manuscript: SvdP, CCB, TJMV, ADIvA. Critical revision of paper for important intellectual content: SvdP, DEMCJ, AvdV, CCB, TJMV, AWF, MJP, ADIvA. Statistical analysis: SvdP. Obtaining funding: AvdV, CCB, TJMV, MJP. Administrative, technical or logistic support: SvdP. Supervision: DEMCJ, AWF, MJP, ADIvA.
